Cyclosporine A in chronic lymphocytic leukemia: dual anti-leukemic and immunosuppressive role?
The association of hemolytic anemia and other autoimmune cytopenias with chronic lymphocytic leukemia (CLL) is well known. The etiology of these immune syndromes is still uncertain, despite evidence that the putative cell of origin of the B-CLL cell produces naturally occurring autoantibodies. Cyclosporine A is effective in treating the immune manifestations associated with CLL and, occasionally, has shown anti-leukemic activity. We report two cases in which cyclosporine A treatment of autoimmune hemolytic anemia resulted in reduction of CLL cell burden. We then discuss the possible mechanism of action of cyclosporine A and the nature of the autoimmune processes involved.
Wright
S J
SJ
University of Texas, M.D. Anderson Cancer Center, Houston, USA.
Keating
M J
MJ
D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D007958:Leukocyte Count; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D015703:Antigens, CD; D000970:Antineoplastic Agents; D006454:Hemoglobins; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D014740:Vidarabine; C024352:fludarabine